Publications by authors named "Hamid Shidban"
As part of the Spare-the-Nephron trial, we evaluated the combination mycophenolate mofetil (MMF) and sirolimus (SRL) as a calcineurin inhibitor (CNI)-free regimen for the preservation of renal function in renal allograft recipients. This 2-year, open-label, multicenter trial randomized 299 patients of which 151 were maintained on MMF and a CNI, 148 on MMF plus SRL (n=120, tacrolimus; n=31, cyclosporine). Baseline characteristics including measured (iothalamate) glomerular filtration rate (GFR) were similar between groups.
View Article and Find Full Text PDFArticle Synopsis
- Chronic Allograft Nephropathy (CAN) continues to pose a significant challenge for kidney transplant patients, highlighting the need for non-invasive biomarkers to predict graft loss and manage immunosuppression.
- The study utilized advanced techniques like DNA microarrays and proteomics to identify thousands of genomic and proteomic markers for different stages of CAN in blood samples from kidney transplant patients.
- Findings revealed unique gene and protein profiles for mild and moderate/severe CAN, with high predictive accuracies that pave the way for future clinical validation and potential proteogenomic classification.
Background: Hepatitis C virus (HCV) is frequently a silent infection in hemodialysis (HD) patients with a prevalence of 8-10%. Improving HCV detection in this population prior to transplantation is critical both for infection control and optimal patient care.
Objectives: To assess the current HCV testing practice of the National Institute for Transplantation (PCR testing of enzyme immunoassay (EIA) positive HD patients) by evaluating a subset of EIA positive and EIA negative samples with the VERSANT HCV RNA Qualitative Assay based on transcription mediated amplification (HCV Qual (TMA)) (sensitivity < or = 9.